LOGIN  |  REGISTER
Recursion
Amneal Pharmaceuticals

Hinge Health reports third quarter 2025 financial results

November 04, 2025 | Last Trade: US$ 0 0.00 0.00

SAN FRANCISCO / Nov 04, 2025 / Business Wire / Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the third quarter ended September 30, 2025.

“With healthcare costs rising dramatically, our mission to automate care delivery has never been more urgent,” said Daniel Perez, Co-Founder and CEO, Hinge Health. “This quarter we surpassed 1.5 million lifetime members, delivered year-over-year revenue growth of 53%, and generated record free cash flow. Our AI-powered platform is transforming care at scale, increasing engagement for our members and reducing healthcare costs for our clients.”

Third Quarter 2025 Financial Highlights:

  • Revenue increased 53% year-over-year to $154.2 million compared to revenue of $100.6 million in Q3 2024.
  • GAAP gross margin was 82% compared to 79% in Q3 2024. Non-GAAP gross margin was 83% compared to 79% in Q3 2024.
  • GAAP loss from operations was $6.1 million compared to GAAP loss from operations of $3.9 million in Q3 2024. Non-GAAP income from operations was $30.4 million compared to non-GAAP loss from operations of $3.7 million in Q3 2024.
  • Net cash provided by operating activities was $82.4 million compared to net cash provided by operating activities of $28.4 million during Q3 2024. Free cash flow was $81.3 million compared to free cash flow of $27.5 million in Q3 2024.
  • Cash, cash equivalents, marketable securities and restricted cash were $496.9 million as of September 30, 2025.

Key Metrics as of September 30, 2025:

  • LTM calculated billings of $624.2 million compared to $416.9 million as of Q3 2024, an increase of 50%.
  • Number of clients increased 25% to 2,560 clients compared to 2,047 clients in Q3 2024.

Financial Outlook:

We are providing the following guidance for our fourth quarter and increased guidance for full year 2025:

  • Q4 2025: We expect our revenue to be between $155 million and $157 million, reflecting year-over-year growth of 33% at the midpoint. We expect our non-GAAP income from operations to be between $34 million and $36 million, compared to non-GAAP income from operations of $21 million in Q4 2024, reflecting year-over-year growth of 63% and non-GAAP operating margin of 22% at the midpoint.
  • Fiscal Year 2025: We are increasing our revenue guidance to be between $572 million and $574 million, reflecting year-over-year growth of 47% at the midpoint. We are increasing our non-GAAP income from operations guidance to be between $106 million and $108 million, compared to non-GAAP loss from operations of $26 million in 2024, reflecting non-GAAP operating margin of 19% at the midpoint.

Statement Regarding Use of Non-GAAP Financial Measures

This press release uses non-GAAP financial measures, which are not calculated in accordance with generally accepted accounting principles of the United States (GAAP). For more information about these non-GAAP financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP, please see the “Non-GAAP Financial Measures” section below.

Moreover, we have not reconciled our non-GAAP income (loss) from operations guidance to GAAP income (loss) from operations because we do not and are not able to provide guidance for GAAP income (loss) from operations due to the uncertainty and potential variability of stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets and adjustments, such as the excess inventory and transition charges, restructuring and other expense and acquisition related expense, which are reconciling items between non-GAAP and GAAP income (loss) from operations. Because such items cannot be provided without unreasonable efforts, we are unable to provide a reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measures. However, such items could have a significant impact on our future GAAP income (loss) from operations.

Hinge Health Earnings Webcast

We will host a conference call and webcast for investors on November 4, 2025 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) to discuss our financial results, business highlights and financial outlook. The live webcast of the conference call can be accessed by registering online at ir.hingehealth.com/events-presentations.

Following completion of the events, a webcast replay will also be available at ir.hingehealth.com for 12 months.

About Hinge Health

Hinge Health is focused on scaling and automating the delivery of health care, starting with musculoskeletal conditions. Leveraging an AI-powered care model, wearable devices and access to expert clinicians, Hinge Health delivers personalized, evidence-based care that helps people move beyond pain, improving member outcomes and experiences and reducing costs for clients. The company is headquartered in San Francisco, California.

Available Information

Our investors and others should note that we announce material information to the public about our company, products and services, and other matters related to our company through a variety of means, including filings with the U.S. Securities and Exchange Commission (“SEC”), the investor relations page on our website (ir.hingehealth.com), press releases, public conference calls, and webcasts in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our obligations under Regulation FD.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” or “will,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our outlook and guidance for the fourth quarter of 2025 and guidance for full year 2025 and our assumptions underlying such guidance; our ability to drive future growth and execute on our goals and strategies; and our expectations regarding our product innovation. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including those more fully described in our filings with the SEC, including in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 11, 2025 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, when filed with the SEC. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.

HINGE HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

unaudited

(in thousands, except par value data)

 

 

 

 

 

 

 

 

 

September 30,

 

December 31,

 

 

2025

 

2024

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

261,342

 

 

$

300,785

 

Short-term marketable securities

 

 

218,685

 

 

 

165,787

 

Accounts receivable, net of allowance for credit losses of $7,251 and $6,470 as of September 30, 2025 and December 31, 2024, respectively

 

 

86,765

 

 

 

42,495

 

Deferred commissions

 

 

29,050

 

 

 

18,615

 

Inventory

 

 

13,812

 

 

 

10,873

 

Prepaid expenses and other current assets

 

 

49,228

 

 

 

44,891

 

Total current assets

 

 

658,882

 

 

 

583,446

 

Long-term marketable securities

 

 

15,077

 

 

 

 

Goodwill

 

 

64,096

 

 

 

61,607

 

Intangible assets, net

 

 

2,736

 

 

 

1,807

 

Property, equipment and software, net

 

 

8,401

 

 

 

7,380

 

Operating lease right-of-use assets

 

 

7,743

 

 

 

9,607

 

Other assets

 

 

12,867

 

 

 

9,412

 

Total assets

 

$

769,802

 

 

$

673,259

 

Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$

53,201

 

 

$

27,853

 

Operating lease liabilities

 

 

4,181

 

 

 

3,814

 

Deferred revenue

 

 

299,695

 

 

 

217,632

 

Total current liabilities

 

 

357,077

 

 

 

249,299

 

Operating lease liabilities, noncurrent

 

 

4,853

 

 

 

7,258

 

Total liabilities

 

 

361,930

 

 

 

256,557

 

 

 

 

 

 

 

 

Redeemable convertible preferred stock:

 

 

 

 

 

 

Redeemable convertible preferred stock; $0.00001 par value

 

 

199,874

 

 

 

851,272

 

Stockholders’ equity (deficit):

 

 

 

 

 

 

Common stock, $0.00001 par value

 

 

 

 

 

 

Class A common stock, $0.00001 par value

 

 

 

 

 

 

Class B common stock, $0.00001 par value

 

 

 

 

 

 

Additional paid-in capital

 

 

1,291,036

 

 

 

88,097

 

Accumulated other comprehensive gain

 

 

53

 

 

 

68

 

Accumulated deficit

 

 

(1,083,091

)

 

 

(522,735

)

Total stockholders’ equity (deficit)

 

 

207,998

 

 

 

(434,570

)

Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)

 

$

769,802

 

 

$

673,259

 

         

HINGE HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

unaudited

(in thousands, except per share data)

       

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

2024

 

2025

 

2024

Revenue

 

$

154,211

 

 

$

100,615

 

 

$

417,134

 

 

$

273,148

 

Cost of revenue

 

 

28,012

 

 

 

21,358

 

 

 

92,939

 

 

 

69,334

 

Gross profit

 

 

126,199

 

 

 

79,257

 

 

 

324,195

 

 

 

203,814

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

31,921

 

 

 

23,785

 

 

 

335,382

 

 

 

78,468

 

Sales and marketing

 

 

63,520

 

 

 

44,570

 

 

 

257,464

 

 

 

131,607

 

General and administrative

 

 

36,851

 

 

 

14,747

 

 

 

304,976

 

 

 

46,559

 

Total operating expenses

 

 

132,292

 

 

 

83,102

 

 

 

897,822

 

 

 

256,634

 

Loss from operations

 

 

(6,093

)

 

 

(3,845

)

 

 

(573,627

)

 

 

(52,820

)

Other income:

 

 

 

 

 

 

 

 

 

 

 

 

Other income, net

 

 

4,455

 

 

 

5,295

 

 

 

14,147

 

 

 

15,399

 

Net income (loss) before income taxes

 

 

(1,638

)

 

 

1,450

 

 

 

(559,480

)

 

 

(37,421

)

Provision for income taxes

 

 

206

 

 

 

1,109

 

 

 

876

 

 

 

1,628

 

Net income (loss)

 

$

(1,844

)

 

$

341

 

 

$

(560,356

)

 

$

(39,049

)

Adjustment to reflect deemed contribution from Series D and Series E redeemable convertible preferred stock extinguishment

 

 

 

 

 

 

 

 

104,174

 

 

 

 

Undistributed earnings attributable to participating securities

 

 

 

 

 

(269

)

 

 

 

 

 

 

Net income (loss) attributable to common stockholders

 

$

(1,844

)

 

$

72

 

 

$

(456,182

)

 

$

(39,049

)

Net income (loss) attributable to common stockholders per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.02

)

 

$

0.01

 

 

$

(9.88

)

 

$

(2.89

)

Diluted

 

$

(0.02

)

 

$

0.01

 

 

$

(9.88

)

 

$

(2.89

)

Weighted average shares used in computing net income (loss) per share attributable to common stockholders:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

78,858

 

 

 

13,623

 

 

 

46,173

 

 

 

13,512

 

Diluted

 

 

78,858

 

 

 

16,584

 

 

 

46,173

 

 

 

13,512

 

                 

HINGE HEALTH, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

unaudited

(in thousands)

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

2024

 

2025

 

2024

Operating activities

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

(1,844

)

 

$

341

 

 

$

(560,356

)

 

$

(39,049

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

1,264

 

 

 

1,416

 

 

 

3,910

 

 

 

4,584

 

Stock-based compensation

 

 

34,847

 

 

 

115

 

 

 

625,837

 

 

 

725

 

Amortization of deferred commissions

 

 

12,566

 

 

 

7,471

 

 

 

32,436

 

 

 

20,882

 

Accretion of discounts and amortization of premiums on marketable securities, net

 

 

50

 

 

 

79

 

 

 

376

 

 

 

296

 

Excess and obsolete inventory charge

 

 

 

 

 

 

 

 

 

 

 

1,812

 

Non-cash operating lease expense

 

 

861

 

 

 

945

 

 

 

2,549

 

 

 

2,778

 

Provision for credit losses

 

 

560

 

 

 

1,452

 

 

 

3,340

 

 

 

3,939

 

Deferred income taxes

 

 

50

 

 

 

 

 

 

146

 

 

 

 

Other

 

 

4

 

 

 

17

 

 

 

2

 

 

 

15

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable

 

 

11,974

 

 

 

6,053

 

 

 

(47,610

)

 

 

(17,228

)

Deferred commissions

 

 

(10,670

)

 

 

(9,530

)

 

 

(38,320

)

 

 

(27,701

)

Inventory

 

 

175

 

 

 

2,691

 

 

 

(2,939

)

 

 

3,828

 

Prepaid expenses and other current assets

 

 

(1,393

)

 

 

(3,731

)

 

 

(8,002

)

 

 

(2,436

)

Other assets

 

 

(7,664

)

 

 

131

 

 

 

(8,149

)

 

 

370

 

Accounts payable and accrued liabilities

 

 

17,993

 

 

 

(495

)

 

 

24,990

 

 

 

(8,156

)

Operating lease liabilities

 

 

(932

)

 

 

(1,226

)

 

 

(2,724

)

 

 

(3,598

)

Deferred revenue

 

 

24,557

 

 

 

22,668

 

 

 

82,062

 

 

 

69,602

 

Net cash provided by operating activities

 

 

82,398

 

 

 

28,397

 

 

 

107,548

 

 

 

10,663

 

Investing activities

 

 

 

 

 

 

 

 

 

 

 

 

Purchase of property and equipment

 

 

(52

)

 

 

(315

)

 

 

(300

)

 

 

(882

)

Capitalized internal use software

 

 

(1,065

)

 

 

(545

)

 

 

(3,401

)

 

 

(1,861

)

Purchases of marketable securities

 

 

(142,898

)

 

 

(80,497

)

 

 

(318,180

)

 

 

(241,265

)

Maturities of marketable securities

 

 

85,258

 

 

 

83,884

 

 

 

249,814

 

 

 

265,434

 

Acquisition of a business

 

 

 

 

 

 

 

 

(4,000

)

 

 

 

Net cash (used in) provided by investing activities

 

 

(58,757

)

 

 

2,527

 

 

 

(76,067

)

 

 

21,426

 

Financing activities

 

 

 

 

 

 

 

 

 

 

 

 

Proceeds from exercise of common stock options

 

 

531

 

 

 

125

 

 

 

787

 

 

 

402

 

Proceeds from issuance of common stock in initial public offering, net of issuance costs

 

 

 

 

 

 

 

 

255,675

 

 

 

 

Tax withholdings on settlement of restricted stock units and performance-based restricted stock units

 

 

 

 

 

 

 

 

(272,258

)

 

 

 

Payment on Repurchase Agreement with Coatue

 

 

 

 

 

 

 

 

(50,000

)

 

 

 

Proceeds from repayment of non-recourse loans to employees

 

 

 

 

 

 

 

 

4,934

 

 

 

 

Payments for deferred offering costs

 

 

 

 

 

(143

)

 

 

(10,061

)

 

 

(269

)

Net cash (used in) provided by financing activities

 

 

531

 

 

 

(18

)

 

 

(70,923

)

 

 

133

 

Net increase (decrease) in cash

 

 

24,172

 

 

 

30,906

 

 

 

(39,442

)

 

 

32,222

 

Cash, cash equivalents and restricted cash, beginning of period

 

 

238,972

 

 

 

238,790

 

 

 

302,586

 

 

 

237,474

 

Cash, cash equivalents and restricted cash, end of period

 

$

263,144

 

 

$

269,696

 

 

$

263,144

 

 

$

269,696

 

Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

261,342

 

 

$

267,534

 

 

$

261,342

 

 

$

267,534

 

Restricted cash

 

 

1,802

 

 

 

2,162

 

 

 

1,802

 

 

 

2,162

 

Total cash, cash equivalents and restricted cash

 

$

263,144

 

 

$

269,696

 

 

$

263,144

 

 

$

269,696

 

Glossary of Terms

LTM Calculated Billings: We believe calculated billings on a last 12-months basis helps investors better understand our performance for a particular period given the seasonality in our model due to quarterly fluctuations based on the timing of new client launches and number of intra-year launches. We anticipate that this seasonality will continue and therefore focus on LTM calculated billings. Our revenue generally does not reflect this seasonality and these quarterly fluctuations given that we recognize revenue ratably over the term that members have access to our platform. LTM calculated billings are defined as total revenue, plus the change in deferred revenue, less the change in contract assets for a given 12-month period.

Number of Clients: We view this number as an important metric to assess the performance of our business as an increased number of clients drives growth, increases brand awareness, and helps provide scale to our business. Clients are defined as businesses or organizations, which we call entities, that have at least one active agreement with us at the end of a particular period. Entities that procure our platform through our partners are counted as individual clients. We do not count our partners as clients, unless they also separately have at least one active client agreement with us. When a partner has an agreement with us for their fully-insured population, that partner is deemed to be one client, despite there being multiple fully-insured employers within that entity that have access to our platform.

Non-GAAP Financial Measures

In addition to our results prepared in accordance with GAAP, we believe the following non-GAAP financial measures, including non-GAAP gross profit and gross margin, non-GAAP income (loss) from operations and operating margin, non-GAAP operating expenses, and free cash flow and free cash flow margin included in this press release, provide users of our financial information with additional useful information in evaluating our performance and liquidity and allows them to more readily compare our results across periods without the effect of non-cash and other items as detailed below. Additionally, our management and board of directors use our non-GAAP financial measures to evaluate our performance and liquidity, identify trends and make strategic decisions.

There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes. Our non-GAAP financial measures should not be considered in isolation or as alternatives to gross profit, gross margin, income (loss) from operations, net cash provided by (used in) operating activities or any other measure of financial performance calculated and presented in accordance with GAAP.

Non-GAAP Gross Profit and Gross Margin

We define non-GAAP gross profit as gross profit presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including excess and obsolete inventory charges related to our AI-powered motion tracking technology transition, stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets, and restructuring and other expenses. We define non-GAAP gross margin as non-GAAP gross profit divided by revenue.

The principal limitation of non-GAAP gross profit and non-GAAP gross margin is that they exclude significant expenses that are required by GAAP to be recorded in our consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations.

Non-GAAP Income (Loss) From Operations and Operating Margin

We define non-GAAP income (loss) from operations as income (loss) from operations presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including excess and obsolete inventory charges related to our AI-powered motion tracking technology transition, stock-based compensation expense, employer payroll tax expense related to stock-based compensation, amortization of intangible assets, restructuring and other expenses and acquisition-related expenses. We define non-GAAP operating margin as non-GAAP income (loss) from operations divided by revenue.

The principal limitation of non-GAAP income (loss) from operations and non-GAAP operating margin is that they exclude significant expenses that are required by GAAP to be recorded in our consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations.

Non-GAAP Operating Expenses

We define non-GAAP operating expenses as operating expenses presented in accordance with GAAP, adjusted to exclude non-cash, non-operational and non-recurring items, including stock-based compensation expense, employer payroll tax expense related to stock-based compensation, restructuring and other expenses and acquisition-related expenses.

The principal limitation of non-GAAP research and development expenses, non-GAAP sales and marketing expenses and non-GAAP general and administrative expenses is that they exclude significant expenses that are required by GAAP to be recorded in our consolidated financial statements, including non-cash expenses, and the impact of non-recurring charges that we do not consider to be indicative of our ongoing core operations.

Free Cash Flow and Free Cash Flow Margin

We define free cash flow as net cash provided by (used in) operating activities plus cash used for employer payroll taxes at IPO related to stock-based compensation less purchases of property, equipment and software (including capitalized internal-use software). We believe that free cash flow is a helpful indicator of liquidity that provides information to management and investors about the amount of cash generated or used by our operations that, after taking into account the employer payroll taxes paid as part of the vesting of shares at IPO as well as investments in property, equipment and software (including capitalized internal-use software), can be used for strategic initiatives, including investing in our business and strengthening our financial position. The principal limitation of free cash flow is that it does not represent the total increase or decrease in our cash balance for a given period. We define free cash flow margin as free cash flow divided by revenue.

We adjust the following items from one or more of our non-GAAP financial measures:

Excess and obsolete inventory charges. We exclude certain charges related to excess and obsolete inventory related to our AI-powered motion tracking technology transition, which was our strategic decision in the first half of 2023 to shift away from providing kits with tablets and wearable sensors. As part of this shift, we began to provide access to our platform through our app on members’ personal smartphones or tablets and replaced sensors for members with our proprietary AI-powered motion tracking technology. We exclude these charges because we do not believe these expenses have a direct correlation to the operating performance of our business.

Stock-based compensation expense. We exclude stock-based compensation expense, which is a non-cash expense, from certain of our non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding our operating performance.

Employer payroll tax expense related to stock-based compensation. We exclude expenses for employer payroll taxes related to stock-based compensation from certain of our non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding operational performance. In particular, this expense is tied to the exercise, vesting or sale of underlying equity awards and the price of our common stock at the time of exercise, vesting or sale which may vary from period to period independent of the operating performance of our business.

Amortization of intangible assets. We exclude amortization of intangible assets, which is a non-cash expense, from certain of our non-GAAP financial measures. Our expenses for amortization of intangible assets are inconsistent in amount and frequency because they are significantly affected by the timing, size of acquisitions and the inherent subjective nature of purchase price allocations. We exclude these amortization expenses because we do not believe these expenses have a direct correlation to the operating performance of our business.

Restructuring and other expenses. We exclude certain charges that are mainly attributable to workforce reduction in order to simplify our operations and better align our resources with our priorities. We exclude these charges because we do not believe these charges have a direct correlation to the operating performance of our business.

Acquisition-related expenses. We exclude certain charges that are attributable to acquiring businesses. We exclude these charges because we do not believe these charges have a direct correlation to the operating performance of our business.

HINGE HEALTH, INC.

unaudited

(in thousands, except percentages)

       

Reconciliation of GAAP to Non-GAAP Financial Measures:

       

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

2024

 

2025

 

2024

GAAP gross profit

 

$

126,199

 

 

$

79,257

 

 

$

324,195

 

 

$

203,814

 

GAAP gross margin

 

 

82

%

 

 

79

%

 

 

78

%

 

 

75

%

Excess and obsolete inventory charges (1)

 

 

 

 

 

 

 

 

 

 

 

1,812

 

Stock-based compensation expense (2)

 

 

1,401

 

 

 

22

 

 

 

17,842

 

 

 

94

 

Employer payroll tax expense related to stock-based compensation

 

 

40

 

 

 

 

 

 

933

 

 

 

 

Amortization of intangible assets

 

 

224

 

 

 

94

 

 

 

630

 

 

 

284

 

Restructuring and other expenses

 

 

 

 

 

(20

)

 

 

 

 

 

691

 

Non-GAAP gross profit

 

$

127,864

 

 

$

79,353

 

 

$

343,600

 

 

$

206,695

 

Non-GAAP gross margin

 

 

83

%

 

 

79

%

 

 

82

%

 

 

76

%

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

2024

 

2025

 

2024

GAAP loss from operations

 

$

(6,093

)

 

$

(3,845

)

 

$

(573,627

)

 

$

(52,820

)

GAAP operating margin

 

 

(4

)%

 

 

(4

)%

 

 

(138

)%

 

 

(19

)%

Excess and obsolete inventory charges (1)

 

 

 

 

 

 

 

 

 

 

 

1,812

 

Stock-based compensation expense (2)

 

 

34,847

 

 

 

115

 

 

 

625,837

 

 

 

725

 

Employer payroll tax expense related to stock-based compensation

 

 

228

 

 

 

 

 

 

14,455

 

 

 

(6,253

)

Amortization of intangible assets

 

 

224

 

 

 

94

 

 

 

630

 

 

 

284

 

Restructuring and other expenses

 

 

 

 

 

(44

)

 

 

 

 

 

8,627

 

Acquisition-related expenses

 

 

1,171

 

 

 

 

 

 

4,139

 

 

 

100

 

Non-GAAP income (loss) from operations

 

$

30,377

 

 

$

(3,680

)

 

$

71,434

 

 

$

(47,525

)

Non-GAAP operating margin

 

 

20

%

 

 

(4

)%

 

 

17

%

 

 

(17

)%

(1) Reflects our strategic decision in the first half of 2023 to shift away from providing kits with tablets and wearable sensors. As part of this shift, we began to provide access to our platform through our app on members’ personal smartphones or tablets and replaced all sensors for members with our proprietary AI-powered motion tracking technology.

 

(2) Stock-based compensation expense:

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

2024

 

2025

 

2024

Cost of revenue

 

$

1,401

 

 

$

22

 

 

$

17,842

 

 

$

94

 

Research and development

 

 

8,259

 

 

 

36

 

 

 

257,068

 

 

 

198

 

Sales and marketing

 

 

5,960

 

 

 

36

 

 

 

101,010

 

 

 

217

 

General and administrative

 

 

19,227

 

 

 

21

 

 

 

249,917

 

 

 

216

 

 

 

$

34,847

 

 

$

115

 

 

$

625,837

 

 

$

725

 

                 

HINGE HEALTH, INC.

unaudited

(in thousands, except for percentages)

       

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

2024

 

2025

 

2024

GAAP research and development

 

$

31,921

 

 

$

23,785

 

 

$

335,382

 

 

$

78,468

 

GAAP research and development as a
percentage of revenue

 

 

21

%

 

 

24

%

 

 

80

%

 

 

29

%

Stock-based compensation expense (1)

 

 

(8,259

)

 

 

(36

)

 

 

(257,068

)

 

 

(198

)

Employer payroll tax expense related to stock-based compensation

 

 

(145

)

 

 

 

 

 

(7,165

)

 

 

2,852

 

Restructuring and other expenses

 

 

 

 

 

110

 

 

 

 

 

 

(4,283

)

Acquisition-related expenses

 

 

(1,157

)

 

 

 

 

 

(3,975

)

 

 

 

Non-GAAP research and development

 

$

22,360

 

 

$

23,859

 

 

$

67,174

 

 

$

76,839

 

Non-GAAP research and development as a percentage of revenue

 

 

14

%

 

 

24

%

 

 

16

%

 

 

28

%

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

2024

 

2025

 

2024

GAAP sales and marketing

 

$

63,520

 

 

$

44,570

 

 

$

257,464

 

 

$

131,607

 

GAAP sales and marketing as a
percentage of revenue

 

 

41

%

 

 

44

%

 

 

62

%

 

 

48

%

Stock-based compensation expense (1)

 

 

(5,960

)

 

 

(36

)

 

 

(101,010

)

 

 

(217

)

Employer payroll tax expense related to stock-based compensation

 

 

(27

)

 

 

 

 

 

(2,657

)

 

 

 

Restructuring and other expenses

 

 

 

 

 

(61

)

 

 

 

 

 

(2,114

)

Non-GAAP sales and marketing

 

$

57,533

 

 

$

44,473

 

 

$

153,797

 

 

$

129,276

 

Non-GAAP sales and marketing as a percentage of revenue

 

 

37

%

 

 

44

%

 

 

37

%

 

 

47

%

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

2024

 

2025

 

2024

GAAP general and administrative

 

$

36,851

 

 

$

14,747

 

 

$

304,976

 

 

$

46,559

 

GAAP general and administrative as a percentage of revenue

 

 

24

%

 

 

15

%

 

 

73

%

 

 

17

%

Stock-based compensation expense (1)

 

 

(19,227

)

 

 

(21

)

 

 

(249,917

)

 

 

(216

)

Employer payroll tax expense related to stock-based compensation

 

 

(16

)

 

 

 

 

 

(3,700

)

 

 

3,401

 

Restructuring and other expenses

 

 

 

 

 

(25

)

 

 

 

 

 

(1,539

)

Acquisition-related expenses

 

 

(14

)

 

 

 

 

 

(165

)

 

 

(100

)

Non-GAAP general and administrative

 

$

17,594

 

 

$

14,701

 

 

$

51,194

 

 

$

48,105

 

Non-GAAP general and administrative as a percentage of revenue

 

 

11

%

 

 

15

%

 

 

12

%

 

 

18

%

(1) For details on stock-based compensation expense, see above.

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

2024

 

2025

 

2024

Net cash provided by operating activities

 

$

82,398

 

 

$

28,397

 

 

$

107,548

 

 

$

10,663

 

Operating cash flow margin

 

 

53

%

 

 

28

%

 

 

26

%

 

 

4

%

Adjustment for employer taxes at IPO related to stock-based compensation

 

 

 

 

 

 

 

 

14,227

 

 

 

 

Less purchases of property, equipment and software (including capitalized internal use software)

 

 

(1,117

)

 

 

(860

)

 

 

(3,701

)

 

 

(2,743

)

Free cash flow

 

$

81,281

 

 

$

27,537

 

 

$

118,074

 

 

$

7,920

 

Free cash flow margin

 

 

53

%

 

 

27

%

 

 

28

%

 

 

3

%

Net cash (used in) provided by investing activities

 

$

(58,757

)

 

$

2,527

 

 

$

(76,067

)

 

$

21,426

 

Net cash (used in) provided by financing activities

 

$

531

 

 

$

(18

)

 

$

(70,923

)

 

$

133

 

 

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page